ArticlePediatric nephrology (Berlin, Germany)2026

Evaluation of the comparative efficacy and safety of obinutuzumab and other follow-up strategies after rituximab failure in refractory nephrotic syndrome.

Haoyu Zha et al.PubMed ↗Publisher ↗

No numbers read from the abstract.